Regencell Bioscience Holdings Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Annual Report on Form 20-F for the Fiscal Year Ending June 30, 2026 | 31 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Research and Development (R&D) Expenses Annually950K
Cash and Cash Equivalents Quarterly2.4M
Watch Items
- U.S. Department of Justice (DOJ) InvestigationTrigger: Any formal charges, settlement announcements, or expansion of the subpoena scopeAction: Re-evaluate legal risk provisions and assess potential impact on the company's going concern status.
- Securities Class Action Lawsuit (Lead Plaintiff Deadline June 23, 2026)Trigger: Appointment of lead plaintiff and subsequent filing of an amended consolidated complaintAction: Monitor court dockets for motion rulings and assess potential financial liability or settlement requirements.
- Transition of Independent Registered Public Accounting FirmTrigger: Completion of the first audit by HTL International, LLC for the fiscal year ending June 30, 2026Action: Review the audited financial statements for any changes in accounting treatments, internal control assessments, or going concern modifications.
Research as of 19 Jun 2026